Skip to main content
Premium Trial:

Request an Annual Quote

Helio Health, China's National Cancer Center Partner to Develop Blood-Based Liver Cancer Diagnostic

NEW YORK – Helio Health said on Wednesday that it will partner with China's National Cancer Center to launch a prospective study evaluating the performance of the Helio Liver Test in real-world screening scenarios.

The project will be supported by a grant worth an undisclosed amount from the Ministry of Science and Technology, said Irvine, California-based Helio.

Helio Health's blood-based assay combines methylation data, protein biomarkers, and a patient's demographic information into a patented algorithm to determine if they have early-stage hepatocellular carcinoma.

The new study will measure the sensitivity and specificity of the Helio Liver test compared with current standards of care for the detection of liver cancer in about 3,000 patients in China.

"This particular study is uniquely designed to evaluate the test in a larger screening population and will allow us to gain a better understanding of the real-world application for this important technology, including across rural parts of China where access to cancer detection and screening tests is often limited," Kenneth Chahine, CEO of Helio Health, said in a statement.

Helio Health previously launched a multicenter collaboration in September to compare the performance of the early-stage HCC diagnostic test.